Zydus Lifesciences Approves Share Buyback of Up to 95.65 Lakh Equity Shares
Zydus Lifesciences Limited has announced a plan to acquire its own equity shares through a buyback, following the approval granted by its Board of Directors on May 19, 2026. The buyback is structured to maximize shareholder participation via a tender offer.The company approved the buyback of not exceeding 95,65,217 fully paid-up equity shares. Each share has a face value of INR 1/-. The purchase will be done at a Buyback Price of INR 1,150/- per Equity Share.
The total aggregate value of the buyback is set at not exceeding INR 1100,00,00,000/- (Indian Rupees One Thousand One Hundred Crores only).
Key Details of the Buyback
The resolution specifies the financial parameters and proportions of the transaction as follows:| Metric | Value | Proportion |
|---|---|---|
| Maximum Shares Buyback | 95,65,217 shares | 5.16% of paid-up equity share capital |
| Buyback Price (Per Share) | INR 1,150/- | N/A |
| Maximum Total Value | INR 1100,00,00,000/- | 3.84% of free reserves |
| Record Date | Friday, May 29, 2026 | N/A |
Implementation and Operational Framework
The buyback will be implemented through a tender offer route, inviting participation from all equity shareholders and beneficial owners of the company. The shares will be acquired from the eligible shareholders who hold the shares as of the Record Date, May 29, 2026.The company confirmed that the proposed buyback amount does not exceed the statutory limits of 10% of the aggregate of the fully paid-up equity share capital and free reserves of the Company as of March 31, 2026, based on both standalone and consolidated financial statements.
The buyback process will utilize the 'Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers' and requires the Company to approach the National Stock Exchange of India (NSE) to facilitate the transaction.
To manage the process, the Board of Directors constituted a Buyback Committee. Furthermore, Zydus Lifesciences appointed several key professionals and intermediaries:
- Manager and Buying Broker: ICICI Securities Limited
- Escrow Agent: ICICI Bank Limited
- Legal Advisors: M/s Khaitan & Co
- Registrar to the Buyback: MUFG Intime India Private Limited
The Board also confirmed that the Company will ensure the consequent reduction of its share capital post buyback, with the purchased equity shares to be extinguished and physically destroyed within the specified timelines.
ZYDUSLIFE Stock Price Movement
Zydus Lifesciences Limited shares rallied on Tuesday, closing higher at ₹1018.9, up 2.68% for the session. The equity saw considerable interest, with total traded volume reaching 5.88 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.